Logo

Janssen Presents Results of Darzalex (daratumumab) in P-III MAIA Study for Transplant Ineligible Patients with Multiple Myeloma at EHA 2021

Share this

Janssen Presents Results of Darzalex (daratumumab) in P-III MAIA Study for Transplant Ineligible Patients with Multiple Myeloma at EHA 2021

Shots:

  • The P-III MAIA study assessing Darzalex + lenalidomide & dexamethasone (DRd) vs Rd in 737 newly diagnosed patients aged 45-90yrs. with MM ineligible for high-dose CT & ASCT
  • MAIA longer-term follow-up analysis showed i.e @5yrs.- OS rate (66% vs 53%)- PFS rate (53% vs 29%)- ORR (93% vs 82%) & median time to next treatment (not reached vs 42.4 mos.)- no new safety concerns were identified
  • The prespecified interim analysis after a median follow-up of 56.2mos. showed a 32% reduction in risk of death- m-OS was not reached- mPFS (not reached vs 34.4mos.) PFS benefit with 47% reduction in risk of disease progression or death

  Ref: PR Newswire | Image: Janssen 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions